A hepatitis B immune globulin (HBIg) approved by the FDA to both prevent hepatitis B virus (HBV) recurrence following liver transplantation in HBsAg-positive patients and provide post-exposure prophylaxis 1-3 Indications and Important Safety Information for HepaGam B Indications HepaGam B [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following: Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients Post-exposure prophylaxis including: Acute exposure to HBsAg-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), Perinatal exposure of infants born to HBsAg-positive mothers, Sexual exposure to HBsAg-positive persons, and Household exposure to persons with acute HBV infection
Nature offers powerful tools to rejuvenate your liver
The peptide crosslinker, GKK C GPQG IWGQ C KKG was synthesized using standard solid-phase peptide synthesis on FMOC-Gly-Wang resin (EMD) on a Liberty 1 Microwave-Assisted Peptide Synthesizer (CEM) with UV monitoring, as previously described 4,5,37
W.ErkerT.MacaulayN.et al (2015)
Concentration-dependent cytotoxicity was observed as 5800 M gave a lower cell viability as compared to 580 M
Q8: Are BPC-157 and TB-500 FDA-approved
